IEX · 8-K · 20261028PR000026

Guidance and Outlook

IDEX CORP /DE/ · 2026-10-28 · Importance 61 · Surprise 76

IDEX raised its full-year 2026 organic sales growth projection to 6.5%–6.8%, from prior guidance of 5%–6%. It also increased its adjusted diluted EPS range to $8.91–$8.96, from $8.70–$8.85. At the midpoint, the revised EPS outlook represents approximately 12% year-over-year growth; management cited strong year-to-date performance, improved visibility, and momentum entering the end of 2026.

Key facts

• IDEX’s HST segment had restructuring-related costs associated with the anticipated closure of a facility, including accelerated depreciation of $0.7 million in the third quarter and $1.2 million in the first nine months of 2026. source
• IDEX incurred $3.4 million of restructuring expenses and asset impairments in the third quarter of 2026, compared with $0.1 million in the prior-year quarter. source